Nxera Pharma Co Ltd (4565)

Currency in JPY
883.0
-7.0(-0.79%)
Closed·
4565 Scorecard
Full Analysis
High shareholder yield
4565 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
869.0896.0
52 wk Range
668.01,747.0
Key Statistics
Bid/Ask
882.00 / 887.00
Prev. Close
890
Open
895
Day's Range
869-896
52 wk Range
668-1,747
Volume
731.8K
Average Volume (3m)
739.89K
1-Year Change
-40.66%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4565 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,827.8
Upside
+107.00%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Nxera Pharma Co Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Nxera Pharma Co Ltd Company Profile

Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist in phase 2 trial for narcolepsy and preclinical trial for EDS in neurology. Its products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; PF-06954522, a GLP-1 agonist for metabolic diseases; and NBI-1117570, a dual muscarinic M1/M4 agonist, NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; NXE0048149, a GPR52 agonist for schizophrenia; and NXE0039732, an EP4 antagonist for immuno-oncology. The company’s products in preclinical trial comprise NBI-1117567, a muscarinic M1-preferring agonist for neurology; KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. It also develops other discovery-stage drugs. The company has strategic collaborations with Verily, PeptiDream, Tempero Bio, Pharmenable Therapeutics, Kallyope, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Boehringer Ingelheim, Lilly, AbbVie, Biohaven pharmaceuticals, Takeda, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and PrecisionLife. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato-ku, Japan.

Employees
374
Market
Japan

Compare 4565 to Peers and Sector

Metrics to compare
4565
Peers
Sector
Relationship
P/E Ratio
−34.3x10.7x−0.5x
PEG Ratio
−0.360.070.00
Price/Book
1.2x1.2x2.6x
Price / LTM Sales
2.6x1.4x3.3x
Upside (Analyst Target)
92.5%1.2%43.5%
Fair Value Upside
Unlock6.2%6.8%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1,827.8
(+107.00% Upside)

Earnings

Latest Release
Aug 08, 2025
EPS / Forecast
-- / 17.83
Revenue / Forecast
-- / 10.15B
EPS Revisions
Last 90 days

4565 Income Statement

FAQ

What Stock Exchange Does Nxera Pharma Trade On?

Nxera Pharma is listed and trades on the Tokyo Stock Exchange stock exchange.

What Is the Stock Symbol for Nxera Pharma?

The stock symbol for Nxera Pharma is "4565."

What Is the Nxera Pharma Market Cap?

As of today, Nxera Pharma market cap is 79.38B.

What Is Nxera Pharma's Earnings Per Share (TTM)?

The Nxera Pharma EPS (TTM) is -25.79.

When Is the Next Nxera Pharma Earnings Date?

Nxera Pharma will release its next earnings report on 06 Nov 2025.

From a Technical Analysis Perspective, Is 4565 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Nxera Pharma Stock Split?

Nxera Pharma has split 2 times.

How Many Employees Does Nxera Pharma Have?

Nxera Pharma has 374 employees.

What is the current trading status of Nxera Pharma (4565)?

As of 09 Aug 2025, Nxera Pharma (4565) is trading at a price of 883.00, with a previous close of 890.00. The stock has fluctuated within a day range of 869.00 to 896.00, while its 52-week range spans from 668.00 to 1,747.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.